|
|
|
|
|
|
|
15.05.26 - 03:27
|
Gilead Prices $3 Billion of Senior Unsecured Notes (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing in 2031 and $500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions.
Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions or other business opportunities.
Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc. are acting as lead joint book-running managers in the offering. The off...
|
|
|
|
|
14.05.26 - 13:06
|
Veeva Commercial Summit to Feature Biopharma′s AI Successes and the Path to Agentic Commercial (PR Newswire)
|
|
|
argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will showcase the future of......
|
|
|
|
|
12.05.26 - 17:42
|
Tubulis-Käufer Gilead setzt bei Arcellx die Axt an (Börsen-Zeitung)
|
|
|
Der US-Pharmakonzern Gilead hat Arcellx Ende April für fast 8 Mrd. Dollar geschluckt und kurz darauf fast alle Mitarbeitenden der Biotechfirma entlassen. Vor kurzem hat Gilead auch die Übernahme des Münchner Krebsspezialisten Tubulis angekündigt – den Abschluss des Deals erwarten die Amerikaner noch in diesem Quartal....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.26 - 00:54
|
Gilead Sciences Inc. Reports Advance In Q1 Income (AFX)
|
|
|
FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) reported earnings for its first quarter that Increases, from last yearThe company's earnings totaled $2.02 billion, or $1.61 per share. This com......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
